Table 1.
Characteristics of older adults newly prescribed and not prescribed ezetimibe within six months of a hospital discharge for an AMI
| No Ezetimibe Prescription N = 69, 895 | New Ezetimibe Prescription N = 1230 | Standardized Difference | |||
|---|---|---|---|---|---|
| Age | N | % | N | % | |
| Mean (SD) | 78.42 | 7.72 | 74.84 | 6.43 | 50% |
| Median (IQR) | 78 | (72–84) | 74 | (69–79) | |
| Female | 31, 995 | 45.8% | 559 | 45.4% | 1% |
| Rural location | 11, 497 | 16.4% | 224 | 18.2% | 5% |
| Income quintile | |||||
| 1 (lowest) | 15, 454 | 22.1% | 243 | 19.8% | 6% |
| 2 | 14, 762 | 21.1% | 253 | 20.6% | 1% |
| 3 | 14, 028 | 20.1% | 257 | 20.9% | 2% |
| 4 | 13, 162 | 18.8% | 256 | 20.8% | 5% |
| 5 (highest) | 12, 489 | 17.9% | 221 | 18.0% | 0% |
| Long-term care | 3587 | 5.1% | < 6 | < 0.5% | – |
| Year of hospital discharge | |||||
| 2005 | 8390 | 12.0% | 131 | 10.7% | 4% |
| 2006 | 7678 | 11.0% | 174 | 14.1% | 10% |
| 2007 | 7974 | 11.4% | 187 | 15.2% | 11% |
| 2008 | 7786 | 11.1% | 121 | 9.8% | 4% |
| 2009 | 7537 | 10.8% | 114 | 9.3% | 5% |
| 2010 | 7585 | 10.9% | 127 | 10.3% | 2% |
| 2011 | 7530 | 10.8% | 148 | 12.0% | 4% |
| 2012 | 7572 | 10.8% | 117 | 9.5% | 4% |
| 2013 | 7843 | 11.2% | 111 | 9.0% | 7% |
| Rostered to a family physician | 55, 396 | 79.3% | 1015 | 82.5% | 8% |
| Comorbiditiesa | |||||
| Coronary artery disease | 27, 838 | 39.8% | 509 | 41.4% | 3% |
| Stroke/Transient ischemic attack | 3012 | 4.3% | 40 | 3.3% | 5% |
| Diabetes | 64, 973 | 93.0% | 1102 | 89.6% | 12% |
| Peripheral vascular disease | 2199 | 3.1% | 36 | 2.9% | 1% |
| Chronic kidney disease | 8809 | 12.6% | 123 | 10.0% | 8% |
| Dialysis | 1080 | 1.5% | 10 | 0.8% | 7% |
| Hypertension | 64, 745 | 92.6% | 1094 | 88.9% | 13% |
| Liver disease | 1905 | 2.7% | 32 | 2.6% | 1% |
| Congestive heart failure | 14, 634 | 20.9% | 146 | 11.9% | 24% |
| Coronary revascularization | 2555 | 3.7% | 71 | 5.8% | 10% |
| Charlson comorbidity index | |||||
| 0 (no hospitalizations) | 46, 300 | 66.2% | 921 | 74.9% | 19% |
| 1 | 7498 | 10.7% | 114 | 9.3% | 5% |
| 2 | 6248 | 8.9% | 95 | 7.7% | 4% |
| 3 or higher | 9849 | 14.1% | 100 | 8.1% | 19% |
| Healthcare Utilizationb | |||||
| Visit to a family physician | 66, 325 | 94.9% | 1165 | 94.7% | 1% |
| Visit to cardiologist | 32, 321 | 46.2% | 559 | 45.4% | 2% |
| Visit to endocrinologist | 5025 | 7.2% | 106 | 8.6% | 5% |
| Visit to internist | 24, 020 | 34.4% | 393 | 32.0% | 5% |
| Evidence of at least 1 cholesterol test | 35, 060 | 50.2% | 797 | 64.8% | 30% |
| Baseline medicationsc | |||||
| Any statin | 30, 329 | 43.4% | 556 | 45.2% | 4% |
| Statin intensityd | |||||
| Low | 2335 | 3.3% | 29 | 2.4% | 5% |
| Moderate | 20, 626 | 29.5% | 314 | 25.5% | 9% |
| High | 6857 | 9.8% | 205 | 16.7% | 20% |
| Other | 511 | 0.7% | 8 | 0.7% | 0% |
| Fibrates | 1430 | 2.0% | 56 | 4.6% | 15% |
| Thienopyridines | 1576 | 2.3% | 21 | 1.7% | 4% |
| Beta-blocker | 24, 614 | 35.2% | 438 | 35.6% | 1% |
| Angiotensin converting enzyme inhibitor | 25, 701 | 36.8% | 415 | 33.7% | 6% |
| Angiotensin receptor blocker | 14, 131 | 20.2% | 303 | 24.6% | 11% |
Unless indicated, data presented as number and percentage
Standardized differences > 10% are considered meaningful
Cell sizes < 6 are not presented for patient privacy
aComorbidities were ascertained in the 5 years prior to their hospitalization for an AMI
bHealthcare utilization was ascertained in the 1 year prior to their hospitalization for an AMI
cBaseline medications were examined in the 120 days prior to their AMI hospitalization
dIntensity of statin therapy was categorized based upon guideline recommendations from the American College of Cardiology